Evidence map›Paper›PMID 36057262›Full record

ArticleAging2022

Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.

Chen Xu, Yang Li, Wei Su, Zhenfan Wang, Zheng Ma, Lei Zhou, Yongqiang Zhou, Jianchun Chen, Minjun Jiang, Ming Liu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Chen XuDepartment of Urology, Suzhou Ninth People's Hospital, Soochow University, Suzhou 215000, China.
Yang LiDepartment of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Huinan Town, Pudong, Shanghai 201399, China.
Wei SuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Zhenfan WangDepartment of Urology, Suzhou Ninth People's Hospital, Soochow University, Suzhou 215000, China.
Zheng MaDepartment of Urology, Suzhou Ninth People's Hospital, Soochow University, Suzhou 215000, China.
Lei ZhouDepartment of Urology, Suzhou Ninth People's Hospital, Soochow University, Suzhou 215000, China.
Yongqiang ZhouDepartment of Urology, Suzhou Ninth People's Hospital, Soochow University, Suzhou 215000, China.
Jianchun ChenDepartment of Urology, Suzhou Ninth People's Hospital, Soochow University, Suzhou 215000, China.
Minjun JiangDepartment of Urology, Suzhou Ninth People's Hospital, Soochow University, Suzhou 215000, China.
Ming LiuThe State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of Life Sciences, Nanjing University, Nanjing 210023, China.
Soochow University · CNFudan University · CNFudan University Shanghai Cancer Center · CNNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating pieces of evidence suggested that immunotypes may indicate the overall immune landscape in the tumor microenvironment, which were closely related to therapeutic response. The purpose of this study was to classify and define the immune subtypes of clear cell renal cell carcinoma (ccRCC), so as to authenticate the potential immune subtypes that respond to immunotherapy. Transcriptome expression profile and mutation profile data of ccRCC, as well as clinical characteristics used in this study were obtained from TCGA database. There were significant differences in the infiltration of immune cells, immune checkpoints, and antigens between ccRCC and para-cancerous tissues. According to immune components, patients with ccRCC were divided into three immune subtypes, with different clinical and molecular characteristics. Compared with other subtypes, IS2 showed cold immune phenotype, and was associated with better survival. IS1 represented complex immune populations and was associated with poor overall survival (OS) and progression free survival (PFS). Further analysis indicated that expression of immune checkpoints also differed among the three subtypes, and was abnormally up-regulated in IS3. Pathway enrichment analysis indicated that the mTOR signaling pathway was abnormally enriched in IS3, while the TGF_BETA, ANGIOGENESIS and receptor tyrosine kinase signaling pathways were abnormally enriched in IS2. Furthermore, there was an abnormal enrichment of the epithelial-to-mesenchymal transition (EMT) signaling pathway in IS1, which may be associated with a higher rate of metastasis. Finally, SCG2 was screened as a specific antigen of ccRCC, which was not only related to poor prognosis, but also significantly associated with immune cells and immune checkpoints. In conclusion, the immune subtypes of ccRCC may provide new insights into the tumor biology and the precise clinical management of this disease.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsBiomarkers, TumorHumansImmunotherapyPrognosisProtein-Tyrosine KinasesTOR Serine-Threonine KinasesTumor MicroenvironmentBiomarkers, TumorProtein-Tyrosine KinasesTOR Serine-Threonine Kinasesclear cell renal cell carcinomaimmune subtypeimmunotherapytumor immune microenvironment

Identifiers

PMID36057262
PMCPMC9512512
OpenAlexW4294001754

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.